Low Dose Naltrexone in Conjunction With the Wahls Protocol to Reduce the Frequency of Chronic Migraines in a Patient With Multiple Sclerosis: A Case Study

Integr Med (Encinitas)
20 June 2021
https://pubmed.ncbi.nlm.nih.gov/34377098/

Brittany - US: Multiple Sclerosis (MS) (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.

Linda Elsegood: I would like to introduce Brittany from the United States who takes LDN for Vasculitis and Multiple Sclerosis. Thanks for joining me, Brittany.

Brittany: Thank you.

Angela - Wales: Multiple Sclerosis (MS) (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.

Linda Elsegood: I'd like to introduce Angela from Wales who has Multiple Sclerosis. Welcome, Angela!

Angela: Hi, Linda!

Alic - England: Fibromyalgia (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.

Linda Elsegood: I'd like to introduce Alic from England who has fibromyalgia. Welcome. Could you tell me when you were diagnosed with fibromyalgia? 

Jill Cottel, MD - Treating the Zebras in Primary Care (2017 Conference) (LDN, low dose naltrexone)

In this presentation Dr Cottel shares case studies of patients:

36 year old woman with Ehlers-Danlos Syndrome. This lady was started on Low Dose Naltrexone (LDN) at 1.5mg, increased to 3 mg and found she lost her earlier improvement but on going down to a much lower dose she improved significantly. 

Dickson Chemist developed a new formulation of LDN which will hopefully improve the outcomes for patients. This new formulation is a more concentrated liquid in the form of drops which are administered under the tongue and absorbed directly from the mucosal lining of the mouth. This sublingual route produces a more rapid absorption bypassing the liver and digestive tract. There are several potential advantages to this, the drug may be more effective and will not be affected by the presence of food stuffs or the hostile environment of the gut.